It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Brain insulin action regulates eating behavior and energy fluxes throughout the body. However, numerous people are brain insulin resistant. How brain insulin responsiveness affects long-term weight and body fat composition in humans is still unknown. Here we show that high brain insulin sensitivity before lifestyle intervention associates with a more pronounced reduction in total and visceral fat during the program. High brain insulin sensitivity is also associated with less regain of fat mass during a nine year follow-up. Cross-sectionally, strong insulin responsiveness of the hypothalamus associates with less visceral fat, while subcutaneous fat is unrelated. Our results demonstrate that high brain insulin sensitivity is linked to weight loss during lifestyle intervention and associates with a favorable body fat distribution. Since visceral fat is strongly linked to diabetes, cardiovascular risk and cancer, these findings have implications beyond metabolic diseases and indicate the necessity of strategies to resolve brain insulin resistance.
Brain insulin action regulates eating behavior and whole-body energy fluxes, however the impact of brain insulin resistance on long-term weight and body fat composition is unknown. Here, the authors show that high brain insulin sensitivity is linked to weight loss during lifestyle intervention and associates with a favorable body fat distribution.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Tschritter Otto 3 ; Machann Jürgen 4
; Hans-Ulrich, Häring 2 ; Preissl Hubert 5
; Fritsche, Andreas 2 ; Heni Martin 2
1 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany (GRID:grid.452622.5)
2 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany (GRID:grid.452622.5); Eberhard Karls University Tübingen, Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
3 Marienhospital Stuttgart, Vinzenz von Paul Kliniken, Emergency Department, Stuttgart, Germany (GRID:grid.459736.a) (ISNI:0000 0000 8976 658X)
4 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany (GRID:grid.452622.5); University Hospital Tübingen, Section of Experimental Radiology, Department of Diagnostic and Interventional Radiology, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249)
5 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany (GRID:grid.452622.5); Eberhard Karls University Tübingen, Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); German Research Center for Environmental Health (GmbH), Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Eberhard Karls University Tübingen, Department of Pharmacy and Biochemistry, Institute of Pharmaceutical Sciences, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)




